

Supplementary Material

Article Title: Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial

Author(s): Le Xiao, MD^a; Stephen J. Ganocy, PhD^b; Robert L. Findling, MD, MBA^c; Kiki Chang, MD^d; Melissa P. DelBello, MD, MS^e; John M Kane, MD^{f,g,h}; Mauricio Tohen, MD, DrPH, MBAⁱ; Yu-Tao Xiang, MD, PhD^j; and Christoph U. Correll, MD^{f,g,h,*}

DOI Number: <https://doi.org/10.4088/JCP.16m10923>

List of Supplementary Material for the article

1. [eTable 1](#) Change in YMRS Total Score from Baseline to Each of the Follow-up Visits in ER, ENR of Olanzapine and Placebo
2. [eTable 2](#) Predictors for 4 Category Reductions of YMRS Randomized to Olanzapine at Study Endpoint (Week 3 LOCF)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1. Change in YMRS Total Score from Baseline to Each of the Follow-up Visits in ER, ENR of Olanzapine and Placebo

	ER (n = 72)		ENR (n = 32)		PBO (n = 54)		ER vs PBO	ENR vs PBO
Week	Mean	SD	Mean	SD	Mean	SD	p-value	p-value
1	-16.75	7.39	-3.31	3.92	-8.06	7.38	<.001	0.011
2	-18.24	8.76	-9.28	8.03	-7.49	10.56	<.001	0.336
3	-20.25	8.95	-10.22	7.61	-11.11	9.05	<.001	0.674

Bolded p-value: p<0.05.

Patients with ER showed a $\geq 25\%$ reduction from baseline in YMRS Total score.

Abbreviations: ER = early response, ENR = early non-response; PBO = placebo; SD = standard deviation, YMRS = Young's Mania Rating Scale

Supplementary eTable 2. Predictors for 4 Category Reductions of YMRS Randomized to Olanzapine at Study Endpoint (Week 3 LOCF)

Percent Improvement over No Improvement		95%			
Category	Predictor	OR	LCL	UCL	p-value
1 to 24%	Age at onset	1.491	1.064	2.089	0.020
	Days to maximum dose	1.520	1.053	2.195	0.206
	Baseline YMRS score	1.279	1.051	1.556	0.014
	Baseline CDRS-R score	1.112	1.025	1.205	0.010
25 to 49%	Age at onset	1.378	1.031	1.841	0.030
	Days to maximum dose	1.632	1.143	2.330	0.007
	Baseline YMRS score	1.223	1.017	1.472	0.032
	Baseline CDRS-R score	1.073	0.993	1.158	0.074
50 to 74%	Age at onset	1.480	1.096	1.999	0.010
	Days to maximum dose	1.679	1.174	2.400	0.005
	Baseline YMRS score	1.151	0.956	1.387	0.137
	Baseline CDRS-R score	1.065	0.986	1.152	0.110
75%+	Age at onset	1.455	1.072	1.975	0.016
	Days to maximum dose	1.530	1.070	2.186	0.020
	Baseline YMRS score	1.234	1.023	1.488	0.028
	Baseline CDRS-R score	1.069	0.989	1.156	0.091

Bolded p-value: $p < 0.05$.

Multiple Ordinal Logistic Regression Analyses,

- (1) Later age at illness onset has a positive impact on an improved response across all categories.
- (2) Longer days to maximum dose indicate improvement $\geq 25\%$.
- (3) Improvement in 3 of the 4 categories is associated with higher baseline YMRS scores (exception is 50 - 74%).
- (4) Higher baseline CDRS-R scores predict improvement in the $< 25\%$ improvement category only.

Abbreviations: CDRS-R = Children's Depression Rating Scale-Revised, LCL = Lower Confidence Limit, LOCF = Last Observation Carried Forward, OR = Odd Ratio, UCL = Upper Confidence Limit, YMRS = Young's Mania Rating Scale